Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Peritoneal dialysis provides several benefits for patients and should be offered as first line kidney replacement therapy, particularly for fragile patients. Limitation to self-care drove assisted peritoneal dialysis to evolve from family-based care to institutional programs, with specialized care givers. Some European countries have mastered this, while others are still bound by the availability of a volunteer to become responsible for treatment.

Methods: A group of leading nephrologists from 13 European countries integrated real-life application of such therapy, highlighting barriers, lessons learned and practical solutions. The objective of this work is to share and summarize several different approaches, with their intrinsic difficulties and solutions, which might helpperitoneal dialysis units to develop and offer assisted peritoneal dialysis.

Results: Assisted peritoneal dialysis does not mean 4 continuous ambulatory peritoneal dialysis exchanges, 7 days/week, nor does it exclude cycler. Many different prescriptions might work for our patients. Tailoring PD prescription to residual kidney function, thereby maintaining small solute clearance, reduces dialysis burden and is associated with higher technique survival. Assisted peritoneal dialysis does not mean assistance will be needed permanently, it can be a transitional stage towards individual or caregiver autonomy. Private care agencies can be used to provide assistance; other options may involve implementing PD training programs for the staff of nursing homes or convalescence units. Social partners may be interested in participating in smaller initiatives or for limited time periods.

Conclusion: Assisted peritoneal dialysis is a valid technique, which should be expanded. In countries without structural models of assisted peritoneal dialysis, active involvement by the nephrologist is needed in order for it to become a reality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10703983PMC
http://dx.doi.org/10.1007/s40620-023-01765-yDOI Listing

Publication Analysis

Top Keywords

peritoneal dialysis
28
assisted peritoneal
24
dialysis
9
peritoneal
8
european countries
8
assisted
7
assisted europe
4
europe advantages
4
advantages inequities
4
inequities solution
4

Similar Publications

Background: Balancing the risks of thrombotic and bleeding events in people with advanced kidney disease is a clinical challenge.

Objectives: To estimate rates of major adverse thrombotic events (MATEs) and bleeding events in individuals with chronic kidney disease (CKD) stages 4 or 5 or with end-stage kidney disease (ESKD) receiving hemodialysis (HD) or peritoneal dialysis (PD).

Methods: Using administrative claims from a 20% Medicare sample, Optum's de-identified Clinformatics Data Mart Database, and the US Renal Data System from 2016-2019, we identified individuals with CKD stages 4 or 5 and individuals with dialysis-dependent ESKD.

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) is associated with a higher prevalence of valvular diseases and increased mortality from cardiovascular causes. Factors that influence the genesis of cardiac valve calcification (CVC) in these patients are not well-defined.

Objective: To determine the risk factors for valvular calcification in patients with CKD.

View Article and Find Full Text PDF

Objective: Minimal Invasive Dialysis Access (MIDA) for renal dialysis encompasses percutaneous arteriovenous fistula (pAVF) creation and the modified percutaneous Seldinger peritoneal dialysis catheter insertions (pPD). This review examines the impact of MIDA on technical success, maturation rates, patency, clinical benefits, complications, and cost.

Methods: A review was made of the literature on MIDA including pAVF creation and pPD insertion regarding technical success rates, maturation rates, patency, clinical benefits, complications, and cost.

View Article and Find Full Text PDF

Background: Experience with icodextrin use in children on long-term peritoneal dialysis is limited. We describe international icodextrin prescription practices and their impact on clinical outcomes: ultrafiltration, blood pressure control, residual kidney function (RKF), technique and patient survival.

Methods: We included patients under 21 years enrolled in the International Pediatric Peritoneal Dialysis Network (IPPN) between 2007 and 2024, on automated PD with a daytime dwell.

View Article and Find Full Text PDF